Navigation Links
Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
Date:11/12/2013

rom relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to ob
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
2. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
3. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
4. Amgen And Servier Complete Product Collaboration Transaction
5. Amgen Announces 2013 Third Quarter Dividend
6. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
7. Amgen And Servier Announce Product Collaboration
8. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
9. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
10. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
11. Amgen Announces 2013 Second Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that ... with PVM technology , is now available. The ... tool continuously captures high-resolution images under a wide ... prepares a report pairing the most relevant images ... This compelling blend of high resolution images and ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
(Date:12/13/2014)... 12, 2014 Trend lines for photonics ... global economic growth, Eugene Arthurs, CEO of SPIE, ... in a featured talk at OPTIC (Optics and Photonics ... National Chung Hsing University in Taichung. , As examples, ... future energy supplies and soon to hit US$50 billion ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5
... University of Wisconsin-Madison spinoff developing a drug for people with ... $1.6 million, of which it has received the first portion, ... developing drug candidates. , ,Trevor Twose, Mithridion's CEO, said the ... that he may hire six people by the end of ...
... was sent an announcement of pending Illinois broadband legislation ... Here's its synopsis: , Creates the Universal Access to ... Services (CMS) to create and maintain a map of ... publicly held broadband infrastructure shall be available for lease ...
... to a biotech company (it is priority #1, #2, and ... sense) companies are continually faced with the challenge of raising ... article will focus on venture capital financing results for 2005. ... from Burrill and Company's data. Burrill's perspective is more towards ...
Cached Biology Technology:Mithridion raises $1.6M through angel networks 2Proposed Illinois broadband act falls short 2Proposed Illinois broadband act falls short 3Proposed Illinois broadband act falls short 4Proposed Illinois broadband act falls short 5U.S. VC funding flat in 2005 while life science funding grows 2U.S. VC funding flat in 2005 while life science funding grows 3U.S. VC funding flat in 2005 while life science funding grows 4
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... Nov. 17, 2014 The Parenteral Drug Association (PDA) ... agencies will speak and at least seven more will participate ... the Omni Shoreham Hotel in Washington D.C. ... to have significant support from the regulatory agencies in ... in our effort to help advance the use ...
(Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... quality trends in forested streams across the country that are ... The study, which draws on decades, worth of data from ... the value of long-term data in understanding the patterns and ... is published in the current issue of the journal ...
... when DNA sequence data is growing exponentially", says Miami ... of the genes that we identify, we have no ... in a foreign language, waiting to be deciphered." Understanding ... emerged at the forefront of molecular biology. Many groups ...
... the differing fates of individual T cells, researchers have ... response can be effectively modeled. The crucial question: What ... will mobilize to fight an acute infection and which ... basis of the immunological memory? The scientists, findings, published ...
Cached Biology News:Study explores long-term water quality trends in near-pristine streams 2Genomic data are growing, but what do we really know? 2Insights into the immune system, from the fates of individual T cells 2Insights into the immune system, from the fates of individual T cells 3
... samples. Operating head automatically rises at the end of determination; triple-point calibration verification; refrigerator eliminates need for ... ... ... ...
Request Info...
RayBio Human Chemokine Antibody Array 1.1 (8) with Accessory, detects 38 chemokine factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... The CultureWell cell culture ... preparing cultured cells for staining ... use medical-grade silicone gaskets with ... provided sterile and ready to ...
Biology Products: